BRCA1 and breast carcinoma: The review by Cibula which showed a mild to moderate increase in breast cancer risk associated with use of OC showed a further increase in risk when the duration of OC use was at least 4 years before FFTP; the observed HR was comparable with that in women without family history (BRCA1: HR = 1.49; 95% CI 1.05–2.11.